Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

   Active, not recruiting · Not applicable · Wide Neck Bifurcation Intracranial Aneurysms

   NCT04839705 · Microvention, Inc. · 29 U.S. investigators

   $454,339research payments

2. A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

   Recruiting · Phase 3 · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

   NCT06338995 · Eli Lilly and Company · 19 U.S. investigators

   $452,488research payments

3. A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

   Active, not recruiting · Phase 3 · HER2-Positive Primary Breast Cancer

   NCT04622319 · Daiichi Sankyo Inc. · 24 U.S. investigators

   $452,191research payments

4. A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

   Recruiting · Phase 2 · Crohn's Disease

   NCT06958536 · Sanofi US Services Inc. · 18 U.S. investigators

   $451,950research payments

5. Genomic Uniformed-Screening Against Rare Disease In All Newborns

   Recruiting · Not applicable · Early Onset Genetic Conditions With Near Complete Penetrance

   NCT05990179 · Genzyme Corporation · 1 U.S. investigator

   $449,686research payments

6. Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

   Terminated · Phase 1 · Acute Myeloid Leukemia

   NCT06068868 · AbbVie Inc. · 16 U.S. investigators

   $449,167research payments

7. SMP-3124LP in Adults With Advanced Solid Tumors

   Recruiting · Phase 1, Phase 2 · Solid Tumor

   NCT06526819 · Sumitomo Pharma America, Inc. · 7 U.S. investigators

   $448,805research payments

8. Post-Market Surveillance Study to Evaluate the Long-Term Safety and Effectiveness of the LVIS Device

   Enrolling by invitation · Intracranial Aneurysms

   NCT05453240 · Microvention, Inc. · 18 U.S. investigators

   $447,702research payments

9. A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

   Active, not recruiting · Phase 2 · Turner Syndrome

   NCT05690386 · Ascendis Pharma Endocrinology Inc · 17 U.S. investigators

   $446,356research payments

10. A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

    Completed · Phase 3 · Atopic Dermatitis

    NCT05369403 · Eli Lilly and Company · 34 U.S. investigators

    $445,777research payments

11. Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

    Active, not recruiting · Phase 3 · Pneumococcal Immunization

    NCT06824181 · Sanofi Pasteur Inc. · 13 U.S. investigators

    $445,643research payments

12. A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants

    Active, not recruiting · Phase 2 · AADC Deficiency

    NCT04903288 · Ptc Therapeutics, Inc. · 3 U.S. investigators

    $445,233research payments

13. Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

    Active, not recruiting · Phase 1 · Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma

    NCT01829568 · AbbVie Inc. · 1 U.S. investigator

    $445,089research payments

14. A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

    Recruiting · Phase 3 · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

    NCT06545955 · Ferring Pharmaceuticals As · 15 U.S. investigators

    $444,055research payments

15. U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

    Active, not recruiting · Phase 1 · Non-Small Cell Lung Cancer (NSCLC)

    NCT03260491 · Daiichi Sankyo Inc. · 11 U.S. investigators

    $442,209research payments

16. A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

    Enrolling by invitation · Phase 3 · Systemic Lupus Erythematosus

    NCT04976322 · UCB SA · 23 U.S. investigators

    $442,161research payments

17. A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

    Recruiting · Cerebral Adrenoleukodystrophy (CALD)

    NCT06224413 · Genetix Biotherapeutics Inc · 2 U.S. investigators

    $440,483research payments

18. A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

    Active, not recruiting · Phase 3 · Prostatic Neoplasms

    NCT05288166 · Eli Lilly and Company · 30 U.S. investigators

    $440,328research payments

19. An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

    Completed · Phase 3 · Schizophrenia

    NCT05741528 · Sumitomo Pharma America, Inc. · 17 U.S. investigators

    $440,190research payments

20. A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

    Recruiting · Phase 3 · Ulcerative Colitis

    NCT04844606 · Eli Lilly and Company · 8 U.S. investigators

    $439,459research payments

21. Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

    Completed · Phase 2 · Ulcerative Colitis

    NCT03196427 · Takeda Pharmaceuticals U.S.A., Inc. · 11 U.S. investigators

    $437,921research payments

22. A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

    Completed · Phase 3 · Schizophrenia

    NCT04072354 · Sumitomo Pharma America, Inc. · 3 U.S. investigators

    $437,245research payments

23. Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

    Completed · Phase 2 · Chronic Sinusitis

    NCT04362501 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $435,332research payments

24. Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

    Completed · Phase 3 · Non-relapsing Secondary Progressive Multiple Sclerosis

    NCT04411641 · Genzyme Corporation · 26 U.S. investigators

    $435,234research payments

25. Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

    Completed · Phase 2 · Immunoglobulin G4 Related Disease

    NCT04520451 · Sanofi US Services Inc. · 1 U.S. investigator

    $434,564research payments

26. PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

    Active, not recruiting · Phase 2 · Non-small Cell Lung Cancer (NSCLC)

    NCT05553834 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $433,327research payments

27. Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

    Completed · Phase 1 · Respiratory Syncytial Virus Infection

    NCT06237296 · Sanofi Pasteur Inc. · 9 U.S. investigators

    $431,961research payments

28. Pompe Disease Registry Protocol

    Recruiting · Glycogen Storage Disease Type II

    NCT00231400 · Sanofi US Services Inc. · 51 U.S. investigators

    $431,788research payments

29. Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

    Completed · Phase 3 · Acute Coronary Syndrome

    NCT03473223 · Csl Behring · 5 U.S. investigators

    $429,636research payments

30. DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

    Recruiting · Not applicable · Venous Thromboembolism

    NCT05701917 · Stryker Corporation · 33 U.S. investigators

    $429,165research payments

31. Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

    Completed · Phase 1 · Advanced Cancer

    NCT04330664 · Mirati Therapeutics, Inc. · 6 U.S. investigators

    $429,024research payments

32. Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

    Active, not recruiting · Phase 2, Phase 3 · Myelodysplastic Syndromes

    NCT02598661 · Geron Corporation · 9 U.S. investigators

    $427,866research payments

33. An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

    Completed · Phase 1, Phase 2 · Hunter Syndrome

    NCT01506141 · Takeda Pharmaceuticals U.S.A., Inc. · 8 U.S. investigators

    $425,454research payments

34. A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

    Recruiting · Phase 1, Phase 2 · Parkinson's Disease

    NCT06753331 · Sumitomo Pharma America, Inc. · 4 U.S. investigators

    $424,204research payments

35. Early Access Program With Arimoclomol in US Patients With NPC

    Available · Niemann-Pick Disease, Type C

    NCT04316637 · Zevra Therapeutics Inc · 11 U.S. investigators

    $423,933research payments

36. CONVERGE Post-Approval Study (PAS)

    Active, not recruiting · Not applicable · Chronic Atrial Fibrillation

    NCT05393180 · Atricure, Inc. · 21 U.S. investigators

    $423,619research payments

37. Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

    Completed · Phase 3 · Eosinophilic Esophagitis (EoE)

    NCT04394351 · Regeneron Pharmaceuticals, Inc. · 15 U.S. investigators

    $423,580research payments

38. An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

    Recruiting · Phase 1, Phase 2 · Methylmalonic Acidemia

    NCT05295433 · ModernaTX, Inc. · 3 U.S. investigators

    $423,127research payments

39. A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

    Active, not recruiting · Phase 3 · Chronic Rhinosinusitis With Nasal Polyps

    NCT06834347 · Sanofi US Services Inc. · 15 U.S. investigators

    $423,082research payments

40. Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

    Enrolling by invitation · Hemophilia B

    NCT05962398 · Csl Behring · 16 U.S. investigators

    $421,639research payments

41. Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

    Active, not recruiting · Phase 3 · Plasma Cell Myeloma

    NCT04270409 · Sanofi US Services Inc. · 9 U.S. investigators

    $421,316research payments

42. A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

    Completed · Phase 3 · Functional Constipation (FC)

    NCT05652205 · AbbVie Inc. · 36 U.S. investigators

    $419,959research payments

43. Prospective Clinical Registry Evaluating Contemporary MANTA Outcomes

    Completed · Femoral Arteriotomy Closure

    NCT05936996 · Arrow International, Inc. · 9 U.S. investigators

    $419,659research payments

44. Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

    Completed · Phase 2 · Asthma

    NCT05421598 · Sanofi US Services Inc. · 21 U.S. investigators

    $418,244research payments

45. A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

    Recruiting · Phase 3 · Kidney Disease

    NCT06963827 · Takeda Pharmaceuticals U.S.A., Inc. · 16 U.S. investigators

    $416,448research payments

46. A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

    Active, not recruiting · Phase 1, Phase 2 · Glycogen Storage Disease

    NCT05095727 · ModernaTX, Inc. · 5 U.S. investigators

    $415,683research payments

47. Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults

    Completed · Phase 3 · Yellow Fever Immunization

    NCT07002060 · Sanofi Pasteur Inc. · 8 U.S. investigators

    $415,611research payments

48. CapTemY90 for Grade 2/3 NET Liver Metastases

    Recruiting · Phase 2 · Neuroendocrine Tumor Grade 2

    NCT04339036 · Sirtex Medical Inc · 1 U.S. investigator

    $413,927research payments

49. Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

    Active, not recruiting · Phase 2 · Systemic Lupus Erythematosus

    NCT05039840 · Sanofi US Services Inc. · 17 U.S. investigators

    $412,657research payments

50. Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

    Completed · Phase 2 · Mycobacterium Infections, Nontuberculous

    NCT04922554 · Paratek Pharmaceuticals, Inc. · 25 U.S. investigators

    $409,928research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.